Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Squalamine lactate in neovascular AMD
NCT02727881Phase 3Unknown
- Sponsor
- Ohr Pharmaceutical, Inc.
- Start
- Apr 2016
- Primary completion
- Dec 2017
- Modality
- Multivalent & Scaffold-Based Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in neovascular age-related macular degeneration (NVAMD) comparing Squalamine + Ranibizumab with Placebo + Ranibizumab (2 arms). Primary endpoint: Functional change in visual acuity at 9 months. Status: unknown.
02
Drugs
squalamine
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT02727881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02727881.